Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC
NCT05773092Phase 2Active, not recruiting
- Sponsor
- National Cancer Centre Singapore
- Start
- Aug 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tegafur in non-small cell lung cancer (NSCLC), sponsored by National Cancer Centre Singapore. Started Aug 2023; status: active, not recruiting.
02
Drugs
tegafur
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05773092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05773092.